• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Agenus Inc. - Common Stock (NQ:AGEN)

    4.430 -0.360 (-7.52%)
    Streaming Delayed Price Updated: 2:37 PM EDT, Apr 20, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,000,871
    Open 4.550
    Bid (Size) 4.420 (400)
    Ask (Size) 4.430 (500)
    Prev. Close 4.790
    Today's Range 4.360 - 4.700
    52wk Range 1.960 - 7.340
    Shares Outstanding 348,875,959
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026
    From Agenus Inc.
    Via Business Wire
    News headline image
    Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer
    From Agenus Inc.
    Via Business Wire

    Performance

    YTD
    +37.2%
    +37.2%
    1 Month
    +19.4%
    +19.4%
    3 Month
    +31.5%
    +31.5%
    6 Month
    +0.2%
    +0.2%
    1 Year
    +91.8%
    +91.8%

    More News

    Read More
    News headline image
    Agenus to Host March 2026 Stakeholder Webcast Harnessing the Immune System to Advance BOT + BAL Across Tumor Types and Expand Patient Access
    From Agenus Inc.
    Via Business Wire
    News headline image
    Agenus Announces Upcoming AACR 2026 Presentation Evaluating Botensilimab Plus Balstilimab in First-Line MSS Metastatic Colorectal Cancer
    From Agenus Bio
    Via Business Wire
    News headline image
    Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
    From Agenus Inc.
    Via Business Wire
    News headline image
    Agenus Triggers First $20M Contingent Payment Under Zydus Life Sciences Collaboration to Support BOT+BAL Manufacturing Needs
    From Agenus Inc.
    Via Business Wire
    News headline image
    Agenus to Provide Fourth Quarter and Year-end 2025 Financial Report and Corporate Update
    From Agenus Bio
    Via Business Wire
    News headline image
    Agenus Presents Biomarker Data Demonstrating Survival Stratification in MSS mCRC and Other Immunologically Cold Tumors Treated with BOT+BAL
    From Agenus Bio
    Via Business Wire
    News headline image
    Agenus to Present New Data at AACR-IO Exploring Systemic and Tumor Inflammation Biomarkers with BOT/BAL in Immunologically Cold Tumors
    From Agenus Bio
    Via Business Wire
    News headline image
    Agenus (AGEN) Q2 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Agenus Expands Medical Affairs Infrastructure to Support Increasing Physician Requests for Authorized Access to Botensilimab Plus Balstilimab
    From Agenus Inc.
    Via Business Wire
    News headline image
    Agenus to Host First 2026 Stakeholder Webcast
    From Agenus Inc.
    Via Business Wire
    Thursday's session: top gainers and losers ↗
    Via Chartmill
    Which stocks are moving on Thursday? ↗
    Via Chartmill
    These stocks are gapping in today's session ↗
    Via Chartmill
    News headline image
    Agenus Announces Closing of $141M Strategic Collaboration with Zydus Lifesciences to Advance BOT+BAL and Strengthen U.S. Manufacturing Readiness
    From Agenus Inc.
    Via Business Wire
    News headline image
    France Expands National AAC Access for Agenus' Botensilimab + Balstilimab for Ovarian Cancer and Soft-Tissue Sarcomas
    From Agenus Inc.
    Via Business Wire
    News headline image
    Agenus (AGEN) Q3 2024 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Agenus (AGEN) Q1 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Agenus (AGEN) Q4 2024 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Agenus Reports Deep, Durable Responses with Botensilimab + Balstilimab in Highly Refractory Ovarian Cancer, Published in JITC
    From Agenus Inc.
    Via Business Wire
    News headline image
    Agenus to Host End-of-Year Stakeholder Webcast Featuring GI Oncology Leaders and Progress of BOT/BAL
    From Agenus Inc.
    Via Business Wire
    News headline image
    GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era
    From Equity Insider
    Via GlobeNewswire
    News headline image
    Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer to Guide Global Medical Affairs and Early-Access Programs, Including France’s AAC
    From Agenus Inc.
    Via Business Wire
    News headline image
    AGENUS INC (NASDAQ:AGEN) Reports Mixed Q3 2025 Earnings, Driven by One-Time Gain ↗
    Via Chartmill

    Frequently Asked Questions

    Is Agenus Inc. - Common Stock publicly traded?
    Yes, Agenus Inc. - Common Stock is publicly traded.
    What exchange does Agenus Inc. - Common Stock trade on?
    Agenus Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Agenus Inc. - Common Stock?
    The ticker symbol for Agenus Inc. - Common Stock is AGEN on the Nasdaq Stock Market
    What is the current price of Agenus Inc. - Common Stock?
    The current price of Agenus Inc. - Common Stock is 4.430
    When was Agenus Inc. - Common Stock last traded?
    The last trade of Agenus Inc. - Common Stock was at 04/20/26 02:37 PM ET
    What is the market capitalization of Agenus Inc. - Common Stock?
    The market capitalization of Agenus Inc. - Common Stock is 1.55B
    How many shares of Agenus Inc. - Common Stock are outstanding?
    Agenus Inc. - Common Stock has 2B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.